What is Cardiovascular Disease?
心血管疾病（CVD）是影响心脏和血管的一组疾病，是全球最常见的死亡原因。根据WHO1的数据，CVD在2016年在全球范围内大约31％或1790万死亡。
- Hypertension due to high blood pressure
- 心律异常引起的心房颤动，也称为心律不齐
- Chronic ischemic heart disease caused by reduced blood supply to the heart
- Stroke caused due to an interruption of the blood supply to part of the brain
- 心力衰竭是由于心脏无法有效地在身体周围抽血而导致的心力衰竭
- 当心脏的一部分未接受足够的氧气时引起的心绞痛
- 由于血流破坏或破坏心肌的一部分而导致的心肌梗塞
Although the causes of the many different types of CVD are not clear-cut, the risk of getting these heart diseases increases when an individual is suffering from high blood pressure, high cholesterol, or diabetes or is obese or has a family history of CVD. Risk also increases with age and lifestyle behaviors such as smoking, alcohol abuse or inactivity.
Therapy Landscape of Major Heart Diseases
心脏病有多种药物，其中许多用于长期使用。示例包括：
- Statins - cholesterol-lowering medications used for lowering LDL cholesterol levels
- 抗凝剂 - 用于预防血凝块。经常开处方以防止先行或经常性中风
- 利尿剂 - 维持血压
- β受体阻滞剂 - 降低血压，心脏病和心力衰竭
- Angiotensin - Converting Enzyme (ACE) inhibitors - for heart failure and high blood pressure
- Calcium channel blockers - for reducing the workload of the heart.
- Angiotensin II receptor blockers - for reducing blood pressure
心脏病市场：
根据预测链接，大型心脏病处方药销售市场在2018年贡献了670亿美元，自2014年以来的复合年增长率为0.6％，主要是由于2013年底以来对重磅炸弹高血压品牌的一般性侵蚀。展望未来，该市场预计将以5.5％（2018-24）的复合年增长率增长，即即将丧失保护（LOP）和通用入境，将以-2.2％（2024-28）的复合年增长率下降。
The hypertension market is the biggest among the other heart diseases with prescription drug sales contributing $32 billion in 2018, and is expected to grow at a CAGR of 1.7% to 2028. This is followed by atrial fibrillation which had the second-highest sales of $18 billion in 2018 and will maintain its position out to 2028, growing at a CAGR of 1%. The heart disease market forecast for 2028 is shown in Figure 1.
图1：重大心脏病贡献，$，2028
美国是心脏病最大的市场，由于其较高的治疗成本，将在2028年继续占267亿美元。就销售贡献的百分比而言，IT在2028年占32％，预计从2018年到2028年的复合年增长率为2.4％。
Europe and APAC will also see healthy growth in terms of heart disease market while the market in Japan, MENA and AUNZ will be stable. Europe and APAC are expected to account for 27% and 22% of the global market respectively, and the remaining regions will contribute 20% in 2028.
就销售增长百分比而言，在新发射和患者天数增加的推动下，Apac国家将看到最大的销售增长。在数量方面，MENA将观察到最高的增长，其次是美洲。预测，受药物治疗的患者付款量将显示出轻微的增长，在未来10年内，全球平均增长率为1.4％。图2显示了2018年至2028年的销售和数量预测增长率。
由于失去保护事件而掩盖了新的推出，增长了
According to Forecast Link, the heart disease market will see as many as 25 launch events take place by 2023. The impact of these new launches will expand the market by approximately $5.8 billion in 2028 (Figure 3). However, due to the impending LoP of some key drugs and the consequent entry of low-priced generics, there will be a net reduction in the global market of over $21.4 billion in sales, by 2028. IQVIA’s Forecast Link predicts that at least 137 LoP events will take place between 2019-2028.
结论
截至2018年，患者接受CVD的药物中有32％是仿制药，而品牌产品贡献了64％。但是，随着通用用途的比例增加，这种趋势将发生变化，到2028年，多达44％的趋势。对137个品牌的保护将大大增加仿制药的用法。除非将新疗法引入市场，否则仿制药的主导地位将相关，一些地理可能会观察到该疾病领域的销售下降。
References:
https://www.who.int/cardiasculacular_diseases/world-hern-hert-day/en/
https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/cardiac-medications
iqviaForecast Link: Disease will provide you with up-to-date forecasts for your disease of interest, so that you can measure new market opportunities and power your strategic decision making. To find out more, please visitForecast Link: Disease.